Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Lymphotoxin signaling is initiated by the viral polymerase in HCV-linked tumorigenesis.

Simonin Y, Vegna S, Akkari L, Grégoire D, Antoine E, Piette J, Floc'h N, Lassus P, Yu GY, Rosenberg AR, Karin M, Durantel D, Hibner U.

PLoS Pathog. 2013 Mar;9(3):e1003234. doi: 10.1371/journal.ppat.1003234. Epub 2013 Mar 21.

2.

Calpain activation by hepatitis C virus proteins inhibits the extrinsic apoptotic signaling pathway.

Simonin Y, Disson O, Lerat H, Antoine E, Binamé F, Rosenberg AR, Desagher S, Lassus P, Bioulac-Sage P, Hibner U.

Hepatology. 2009 Nov;50(5):1370-9. doi: 10.1002/hep.23169.

PMID:
19711428
3.

A lymphotoxin-driven pathway to hepatocellular carcinoma.

Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO, Bremer J, Iezzi G, Graf R, Clavien PA, Thimme R, Blum H, Nedospasov SA, Zatloukal K, Ramzan M, Ciesek S, Pietschmann T, Marche PN, Karin M, Kopf M, Browning JL, Aguzzi A, Heikenwalder M.

Cancer Cell. 2009 Oct 6;16(4):295-308. doi: 10.1016/j.ccr.2009.08.021. Erratum in: Cancer Cell. 2009 Nov 6;16(5):447.

4.
5.

NOD1 Participates in the Innate Immune Response Triggered by Hepatitis C Virus Polymerase.

Vegna S, Gregoire D, Moreau M, Lassus P, Durantel D, Assenat E, Hibner U, Simonin Y.

J Virol. 2016 Jun 10;90(13):6022-6035. doi: 10.1128/JVI.03230-15. Print 2016 Jul 1.

6.

Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes.

Ahlén G, Derk E, Weiland M, Jiao J, Rahbin N, Aleman S, Peterson DL, Pokrovskaja K, Grandér D, Frelin L, Sällberg M.

Gut. 2009 Apr;58(4):560-9. doi: 10.1136/gut.2007.147264. Epub 2008 Aug 8.

7.
8.

Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system.

Zhu H, Dong H, Eksioglu E, Hemming A, Cao M, Crawford JM, Nelson DR, Liu C.

Gastroenterology. 2007 Nov;133(5):1649-59. Epub 2007 Sep 16.

PMID:
17983809
9.

Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling.

Zhang Y, Wei W, Cheng N, Wang K, Li B, Jiang X, Sun S.

Hepatology. 2012 Nov;56(5):1631-40. doi: 10.1002/hep.25849. Epub 2012 Oct 9.

PMID:
22610915
10.

Hepatic expression of HCV RNA-dependent RNA polymerase triggers innate immune signaling and cytokine production.

Yu GY, He G, Li CY, Tang M, Grivennikov S, Tsai WT, Wu MS, Hsu CW, Tsai Y, Wang LH, Karin M.

Mol Cell. 2012 Oct 26;48(2):313-21. doi: 10.1016/j.molcel.2012.07.032. Epub 2012 Sep 6.

11.

Hepatitis C virus-induced activation of β-catenin promotes c-Myc expression and a cascade of pro-carcinogenetic events.

Higgs MR, Lerat H, Pawlotsky JM.

Oncogene. 2013 Sep 26;32(39):4683-93. doi: 10.1038/onc.2012.484. Epub 2012 Oct 29.

PMID:
23108410
12.

Inhibition of hepatitis C virus (HCV) replication by specific RNA aptamers against HCV NS5B RNA replicase.

Lee CH, Lee YJ, Kim JH, Lim JH, Kim JH, Han W, Lee SH, Noh GJ, Lee SW.

J Virol. 2013 Jun;87(12):7064-74. doi: 10.1128/JVI.00405-13. Epub 2013 Apr 17.

13.
14.

Enhanced nuclear factor-kappa B-associated Wnt-1 expression in hepatitis B- and C-related hepatocarcinogenesis: identification by functional proteomics.

Lee TH, Tai DI, Cheng CJ, Sun CS, Lin CY, Sheu MJ, Lee WP, Peng CY, Wang AH, Tsai SL.

J Biomed Sci. 2006 Jan;13(1):27-39. Epub 2005 Oct 14.

PMID:
16228287
15.

Inhibition of native hepatitis C virus replicase by nucleotide and non-nucleoside inhibitors.

Ma H, Leveque V, De Witte A, Li W, Hendricks T, Clausen SM, Cammack N, Klumpp K.

Virology. 2005 Feb 5;332(1):8-15.

16.

Interleukin-32: a new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis.

Moschen AR, Fritz T, Clouston AD, Rebhan I, Bauhofer O, Barrie HD, Powell EE, Kim SH, Dinarello CA, Bartenschlager R, Jonsson JR, Tilg H.

Hepatology. 2011 Jun;53(6):1819-29. doi: 10.1002/hep.24285. Epub 2011 May 14.

PMID:
21381070
17.

Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.

Dhanak D, Duffy KJ, Johnston VK, Lin-Goerke J, Darcy M, Shaw AN, Gu B, Silverman C, Gates AT, Nonnemacher MR, Earnshaw DL, Casper DJ, Kaura A, Baker A, Greenwood C, Gutshall LL, Maley D, DelVecchio A, Macarron R, Hofmann GA, Alnoah Z, Cheng HY, Chan G, Khandekar S, Keenan RM, Sarisky RT.

J Biol Chem. 2002 Oct 11;277(41):38322-7. Epub 2002 Aug 6.

18.

Lymphotoxins: new targets for hepatocellular carcinoma.

Villanueva A, Savic R, Llovet JM.

Cancer Cell. 2009 Oct 6;16(4):272-3. doi: 10.1016/j.ccr.2009.09.012.

19.

HCV replication suppresses cellular glucose uptake through down-regulation of cell surface expression of glucose transporters.

Kasai D, Adachi T, Deng L, Nagano-Fujii M, Sada K, Ikeda M, Kato N, Ide YH, Shoji I, Hotta H.

J Hepatol. 2009 May;50(5):883-94. doi: 10.1016/j.jhep.2008.12.029. Epub 2009 Feb 27.

PMID:
19303158
20.

Hepatitis C virus NS5A binds to the mRNA cap-binding eukaryotic translation initiation 4F (eIF4F) complex and up-regulates host translation initiation machinery through eIF4E-binding protein 1 inactivation.

George A, Panda S, Kudmulwar D, Chhatbar SP, Nayak SC, Krishnan HH.

J Biol Chem. 2012 Feb 10;287(7):5042-58. doi: 10.1074/jbc.M111.308916. Epub 2011 Dec 19.

Supplemental Content

Support Center